Loading clinical trials...
Loading clinical trials...
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC): Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up (PMCF) Study
Conditions
Interventions
BioPearl™
Locations
10
Belgium
CUB Hôpital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Beaujon Hospital
Clichy, France
CHU Grenobles (Hôpital Michallon)
La Tronche, France
Paul-Brousse Hospital
Villejuif, France
SLK-Kliniken Heilbronn
Heilbronn, Germany
Start Date
February 27, 2024
Primary Completion Date
June 30, 2026
Completion Date
December 30, 2027
Last Updated
January 22, 2025
NCT06707233
NCT06187961
NCT06561399
NCT04224636
NCT06397222
NCT05901194
Lead Sponsor
Terumo Europe N.V.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions